LOGIN  |  REGISTER
Viking Therapeutics
Cue Biopharma

electroCore to Participate at the Planet MicroCap Showcase

April 16, 2025 | Last Trade: US$4.98 0.08 1.63

ROCKAWAY, N.J., April 16, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate in the Planet MicroCap Showcase taking place at the Paris Hotel & Casino in Las Vegas on April 23 & 24, 2025.

Dan Goldberger, CEO, will host a group presentation on Wednesday, April 23, 2025 at 1:30 p.m. PT and host one-on-one meetings throughout both days.

To schedule a one-on-one meeting with Mr. Goldberger, investors are encouraged to reach out to Planet MicroCap or electroCore’s investor relations at This email address is being protected from spambots. You need JavaScript enabled to view it..

About electroCore, Inc.

electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.

For more information, visit www.electrocore.com.

Contact

ECOR Investor Relations
(973) 302-9253
This email address is being protected from spambots. You need JavaScript enabled to view it.

Astria Therapeutics

Stock Quote

Featured Stock

ClearPoint Neuro

ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page